Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FSCC9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,865
Award facts
- Contract value 100% obligated
- $19,865.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $19,865 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The award was issued on January 5, 2026, with an ultimate completion date of January 6, 2026, and carries no set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors for Department of Defense pharmaceutical supply needs.
DMS Pharmaceutical Group has demonstrated substantial federal contracting capability as a critical supplier within the military pharmaceutical supply chain, having received numerous delivery orders from the Defense Logistics Agency's Medical Supply Chain division since October 2025. The company's product portfolio spans branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables serving Department of Defense healthcare facilities worldwide. The parent PPV-G GEN V contract, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499.999 billion with a completion date of December 31, 2036, structuring a 30-month base period with three 30-month option periods that positions DMS Pharmaceutical Group as a key supplier for recurring military medical supply operations globally.
Quick answers
Who was awarded contract SPE2DR26FSCC9?
SPE2DR26FSCC9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FSCC9 worth?
The government has obligated $19,865 on SPE2DR26FSCC9.
Is contract SPE2DR26FSCC9 an order under another contract?
Yes. SPE2DR26FSCC9 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSCC9 competed?
The extent of competition for SPE2DR26FSCC9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award